Comparative Pharmacology
Head-to-head clinical analysis: EMERPHED versus HYDROCODONE BITARTRATE CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
Head-to-head clinical analysis: EMERPHED versus HYDROCODONE BITARTRATE CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
EMERPHED vs HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Hydrocodone: mu-opioid receptor agonist; Chlorpheniramine: histamine H1 receptor antagonist; Pseudoephedrine: sympathomimetic amine, alpha- and beta-adrenergic receptor agonist.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
1 tablet (Hydrocodone 5 mg / Chlorpheniramine 4 mg / Pseudoephedrine 60 mg) orally every 4-6 hours as needed for cough and congestion; maximum 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Hydrocodone: 3.8-6 hours; Chlorpheniramine: 14-25 hours (prolonged in children); Pseudoephedrine: 5-8 hours (pH-dependent urinary excretion).
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Hydrocodone: primarily renal (as conjugated metabolites, norhydrocodone, and unchanged drug); <5% fecal. Chlorpheniramine: renal (as metabolites, ~20% unchanged) and fecal. Pseudoephedrine: renal (>90% unchanged via active tubular secretion).
Category C
Category A/B
Sympathomimetic
Sympathomimetic